Results 261 to 270 of about 718,683 (284)

<p>Current status and future prospects of PARP inhibitor clinical trials in ovarian cancer</p>

Cancer Management and Research, 2019
Ying Feng, Huimin Bai
exaly  

Rucaparib: An emerging parp inhibitor for treatment of recurrent ovarian cancer

Cancer Treatment Reviews, 2018
Erlisa Bardhi, Claudia Marchetti, Ludovico Muzii   +2 more
exaly  

PARP-inhibitor potpourri: A comparative review of class safety, efficacy, and cost

Journal of Oncology Pharmacy Practice, 2020
Emily Hennes
exaly  

Olaparib: an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancer

Future Oncology, 2015
Kathleen Moore, Camille C Gunderson
exaly  

POTENT PARP INHIBITORS

2009
PENNING THOMAS D, THOMAS SHEELA A, HAJDUK PHILIP J, SAUER DARYL R, SARRIS KATHY, GIRANDA VINCENT L   +5 more
openaire   +2 more sources

BMS-536924 sensitizes human epithelial ovarian cancer cells to the PARP inhibitor, 3-aminobenzamide

Gynecologic Oncology, 2009
Walter Gotlieb, Amber Yasmeen, Michael Pollak   +2 more
exaly  

Pyrazoloquinolones are potent parp inhibitors

2007
PENNING THOMAS D, ZHU GUI-DONG, GANDHI VIRAJKUMAR B, GONG JIANCHUN, GIRANDA VINCENT L   +4 more
openaire   +5 more sources

PARP Inhibitors

2006
openaire   +1 more source

Phthalazine derivatives as parp inhibitors

2006
MEVELLEC LAURENCE ANNE, LUDO EDMOND J K, MERTENS JOSEPHUS CAROLUS, VAN DUN JACOBUS A J, SOMERS MARIA V F, WOUTERS WALTER B L   +5 more
openaire   +5 more sources

Recent Study of Dual HDAC/PARP Inhibitor for the Treatment of Tumor

Current Topics in Medicinal Chemistry, 2019
Jianyou Shi, Haiying Lu, Zhongliang Jiang   +2 more
exaly